|Bid||5.76 x 1100|
|Ask||5.78 x 1300|
|Day's Range||5.53 - 5.79|
|52 Week Range||4.75 - 9.11|
|Beta (3Y Monthly)||1.45|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.57|
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
COO of Corbus Pharmaceuticals Holdings Inc (30-Year Financial, Insider Trades) Robert Paul Discordia (insider trades) bought 15,000 shares of CRBP on 08/12/2019 at an average price of $5.86 a share. Continue reading...
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 113.64% and 181.93%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Clinical development of lenabasum on target for 2020 data readouts in lead indications systemic sclerosis and cystic fibrosis; diseases affect ~270,000 people total in U.S., EU.
The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.
Anyone researching Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) might want to consider the historical...
Prior low-level convictions for marijuana possession will be pardoned. Amid this news, one would expect marijuana stocks to run higher, but that’s not happening. Just like a doctor does X-rays to see what is going on inside the human body, investors can do an X-ray of marijuana stocks to figure out what is really going on.
- R&D Day to be live video webcasted on Friday, June 21st at 10:00 AM ET - Norwood, MA, June 17, 2019 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or.
Medical marijuana and recreational marijuana are two high growth sectors in the cannabis industry. Learn about how the two differ, and how you can get into the market.
ACR CRISS score remains ≥ 0.95 (95%) at 21 months in systemic sclerosis open-label extension (OLE) studyCDASI activity score reaches -21.8 points at 16 months in dermatomyositis.
Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that purchasers of Corbus Pharmaceuticals Holdings, Inc. filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between November 14, 2016 and February 28, 2019.
Norwood, MA, May 29, 2019 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating.
New data from ongoing Phase 2 open-label extension of lenabasum in systemic sclerosis and open-label extension data in dermatomyositis studies to be presentedPresentation.
Yuval Cohen became the CEO of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) in 2014. First, this article will...
Norwood, MA, May 15, 2019 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating.
NEW YORK, May 13, 2019 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.
NEW YORK, May 13, 2019 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following.
LOS ANGELES, CA / ACCESSWIRE / May 13, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Corbus Pharmaceuticals Holdings, Inc. ("Corbus" or "the Company") (NASDAQ: CRBP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between November 14, 2016 and February 28, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before May 13, 2019.